Holen Sie sich die Stockscreener-App
4.61
0.43%
-0.02
Handel nachbörslich:
4.59
-0.02
-0.43%
Schlusskurs vom Vortag:
$4.63
Offen:
$4.75
24-Stunden-Volumen:
9,565
Relative Volume:
0.64
Marktkapitalisierung:
$5.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.27M
KGV:
-0.4449
EPS:
-10.3626
Netto-Cashflow:
$-10.59M
1W Leistung:
+18.81%
1M Leistung:
-49.72%
6M Leistung:
-85.94%
1J Leistung:
-90.39%
1-Tages-Spanne:
$4.55
$4.835
1-Wochen-Bereich:
$3.7683
$4.835
52-Wochen-Spanne:
$3.25
$63.20
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Firmenname
Akari Therapeutics Plc Adr
Sektor
Branche
Telefon
(929) 274-7510
Adresse
401 EAST JACKSON STREET, TAMPA
Compare AKTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
4.61 | 5.30M | 0 | -17.27M | -10.59M | -10.36 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2026-01-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2025-07-18 | Eingeleitet | Maxim Group | Buy |
| 2019-01-04 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Hochstufung | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Bestätigt | Chardan Capital Markets | Sell |
| 2016-07-11 | Eingeleitet | Chardan Capital Markets | Sell |
Alle ansehen
Akari Therapeutics Plc Adr Aktie (AKTX) Neueste Nachrichten
Akari Therapeutics (NASDAQ: AKTX) registers 867,023 ADSs after ADS ratio change - Stock Titan
Akari Therapeutics PLC (FRA:CLA1) Stock Price, Trades & News - GuruFocus
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC - Sahm
Total equity of Akari Therapeutics Plc Sponsored ADR – LSX:A4270Y - TradingView — Track All Markets
Long term debt to total assets ratio of Akari Therapeutics Plc Sponsored ADR – FWB:CLA1 - TradingView
Discontinued operations of Akari Therapeutics Plc Sponsored ADR – MUN:CLA1 - TradingView
Akari Therapeutics partners with WuXi XDC on ADC development By Investing.com - Investing.com India
Akari Therapeutics partners with WuXi XDC on ADC development - Investing.com
Who's Buying or Selling Akari Therapeutics PLC (FRA:CLA1) Stock Today? - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Dividend - GuruFocus
Akari Therapeutics PLC (FRA:CLA1)Valuation Measures & Financial Statistics - GuruFocus
Akari Therapeutics PLC Stock Baskets | FRA:CLA1 - GuruFocus
Akari Therapeutics PLC Stock Operating Data - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Stock News, Headlines & Updates - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Stock News, Headlines & Updates - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Valuation - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Dividend - GuruFocus
Akari Therapeutics PLC Stock Baskets | STU:CLA1 - GuruFocus
Akari Therapeutics PLC (STU:CLA1)Valuation Measures & Financial Statistics - GuruFocus
Akari Therapeutics ADR: Dividend historical data and projections - marketscreener.com
Akari Therapeutics ADR: Revenue and Earnings Analysts Forecasts Revisions | AKTX | US00972G4055 - MarketScreener
Akari Therapeutics (NASDAQ: AKTX) sets ADS ratio to 1:80,000 in F-6/A filing - Stock Titan
Akari Therapeutics, Plc Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Akari Therapeutics (NASDAQ: AKTX) outlines ADC oncology strategy - Stock Titan
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Declines By 19.4% - Defense World
Akari Therapeutics revises ADS ratio to maintain Nasdaq compliance - MSN
Get insights into the top gainers and losers of Thursday's after-hours session. - ChartMill
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 - ChartMill
Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules By Investing.com - Investing.com India
Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules - Investing.com South Africa
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Akari Therapeutics (NASDAQ: AKTX) plans 1-for-40 ADS ratio change to meet Nasdaq bid rules - Stock Titan
Director Neal James acquires Akari (AKTX) ADS warrants via placement and note swap - Stock Titan
Akari Therapeutics marks one year under CEO Gaslightwala By Investing.com - Investing.com India
Akari Therapeutics marks one year under CEO Gaslightwala - Investing.com
Akari Therapeutics (AKTX) investors approve multiple warrant exercisability resolutions - Stock Titan
Akari Therapeutics adds Dana-Farber expert to advisory board - Investing.com
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board - Finviz
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board - ChartMill
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference - Sahm
Will Akari Therapeutics Plc Depositary Receipt outperform the market in YEAR2025 Earnings Impact & Free High Return Stock Watch Alerts - mfd.ru
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline - ChartMill
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Sahm
Akari Therapeutics (NASDAQ: AKTX) seeks approval for major warrant exercises - Stock Titan
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors - Sahm
Curious about the stocks that are showing activity after the closing bell on Monday? - Chartmill
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - GlobeNewswire Inc.
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - Sahm
Akari Therapeutics to Present at the 2026 Biotech Showcase - Sahm
Finanzdaten der Akari Therapeutics Plc Adr-Aktie (AKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):